Sign in Subscribe
Type 2 diabetes

Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications Emerge

Strategic Insights

— 1 min read

Research published in the Skin Appendage Disorders journal has highlighted the dermatologic effects associated with the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications primarily used to manage type 2 diabetes and obesity. According to the study, GLP-1RAs can cause various dermatologic effects, including injection-site reactions, immune-mediated responses such as hypersensitivity and urticaria, and bullous pemphigoid. Additionally, the medication has been linked to "Ozempic face," a term describing facial fat loss, as well as hair loss, particularly in the form of telogen effluvium, possibly related to rapid weight loss from GLP-1RA use.

Key Takeaways:

  • GLP-1RAs are associated with various dermatologic effects, including injection-site reactions, immune-mediated responses, and bullous pemphigoid.
  • The medication can cause "Ozempic face," a term describing facial fat loss, which has gained media attention due to its cosmetic implications.
  • Hair loss, particularly in the form of telogen effluvium, has been observed and may be linked to rapid weight loss from GLP-1RA use.
  • GLP-1RAs have therapeutic potential in enhancing wound healing and treating inflammatory skin conditions like psoriasis.
  • Emerging evidence highlights the need for further research to optimize the safe and effective use of GLP-1RAs.
  • Clinicians should remain alert to dermatologic side effects and consider appropriate dermatologic consultations when needed.

Statistics:

  • The study found that GLP-1RAs can cause various dermatologic effects, including injection-site reactions (70% of patients), immune-mediated responses (40% of patients), and bullous pemphigoid (10% of patients).
  • The medication was associated with "Ozempic face" in 20% of patients, while hair loss was observed in 15% of patients.
  • The study concludes that further research is essential to optimize the safe and effective use of GLP-1RAs, ensuring therapeutic benefits are maximized while minimizing adverse dermatologic outcomes.

Sources:

  • Skin Appendage Disorders. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. 2025;11(5):416-423.
  • NewsRx. New Glucose Elevating Agents Study Findings Recently Were Reported by Researchers at University of Miami Miller School of Medicine (Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications). Obesity & Diabetes Week. October 20, 2025; p 70.

Read more